Silence Therapeutics plc (NASDAQ:SLN – Get Rating)’s share price gapped down before the market opened on Tuesday after HC Wainwright lowered their price target on the stock from $95.00 to $80.00. The stock had previously closed at $17.09, but opened at $16.44. HC Wainwright currently has a buy rating on the stock. Silence Therapeutics shares last traded at $16.96, with a volume of 104 shares traded.
Separately, Chardan Capital lowered their price objective on shares of Silence Therapeutics from $33.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 17th.
Institutional Investors Weigh In On Silence Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. bought a new position in shares of Silence Therapeutics in the 1st quarter valued at about $16,742,000. Lombard Odier Asset Management Europe Ltd bought a new position in shares of Silence Therapeutics in the 1st quarter valued at about $29,669,000. Goldman Sachs Group Inc. boosted its stake in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock valued at $18,350,000 after purchasing an additional 205,815 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Silence Therapeutics in the 2nd quarter valued at about $136,000. Finally, UBS Oconnor LLC boosted its stake in shares of Silence Therapeutics by 176.4% in the 3rd quarter. UBS Oconnor LLC now owns 79,636 shares of the company’s stock valued at $786,000 after purchasing an additional 50,820 shares during the last quarter. Institutional investors and hedge funds own 72.14% of the company’s stock.
Silence Therapeutics Trading Down 0.4 %
The company has a market cap of $611.21 million, a P/E ratio of -11.24 and a beta of 1.01. The firm’s 50 day moving average price is $12.26 and its 200-day moving average price is $11.00.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.